Related Experiment Video
Updated: Apr 1, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Association of Blood-Based Biomarkers and Malignant Infarction in Severe Anterior Circulation Ischemic Stroke
Dominik Lehrieder1, Hermann Neugebauer1, Alexander M Kollikowski2
1Department of Neurology, University Hospital Wuerzburg, Wuerzburg, Germany.
Objective:
To determine the association of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) with the development of a malignant infarction in severe anterior circulation ischemic stroke.
Methods:
In this prospective, single-center cohort study, patients with severe acute ischemic stroke due to large vessel occlusion (LVO) in the anterior circulation were included. Malignant infarction was defined by clinical and neuroradiological parameters. Serum biomarkers levels of NfL and GFAP were determined by ultrasensitive ELISA. Univariable and multivariable logistic regression models, along with receiver operating characteristics (ROC) characteristic analyses, were performed to assess the predictive value of sNfL and sGFAP.
Results:
Between 06/2020 and 09/2022, 383 patients were included [54.6% female, median age 79 (interquartile range, (IQR) 69-84) years, median NIHSS Score on admission 14 (IQR 9-17)]. Biomarker serum levels were measured at a median of 36 [IQR 23-61] hours after symptom onset. Malignant infarction occurred in 83 patients (21.7%). Both sNfL and sGFAP levels were significantly elevated in patients with compared to those without malignant infarction (sNfL: 208 pg/ml vs. 96 pg/ml, p < 0.001; sGFAP: 36.6 ng/ml vs. 4.1 ng/ml, p < 0.001). After adjusting for clinical and radiological parameters, sNfL and sGFAP remained independent predictors for malignant infarction (sNfL: OR 2.91 [1.55-5.45], p < 0.001; sGFAP: 3.49 [1.80-6.75], p < 0.001). The inclusion of both biomarkers in prediction models significantly improved their predictive value.
Conclusions:
Serum NfL and GFAP independently predict malignant infarction in severe anterior circulation ischemic stroke, albeit with only a low effect size in models with established prognostic factors. Further studies investigating earlier and serial biomarker measurement are required to improve prognostic models supporting risk stratification and decision making.
Study Registration:
DRKS00022064.In severe anterior circulation ischemic stroke due to LVO, sNfL and sGFAP levels were significantly elevated in patients who developed malignant infarction. Both biomarkers independently predicted malignant infarction after adjustment for clinical and radiological factors. Nevertheless, the additional predictive value beyond established prognostic parameters was modest.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

